Skip to content

Study · Case report or series · n = 2 · 2023

3 results

Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports.

Ouellette S, Frias G, Shah R, Alamgir M, Wassef C

Journal of drugs in dermatology : JDD1 Apr 2023Cited by 11 (Europe PMC)

PMID37026881 (opens in a new tab)DOI10.36849/jdd.6550 (opens in a new tab)PepBankPUB-37026881
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In both patients, symptoms began to resolve within 1 month of discontinuing semaglutide.

    In plain wordsIn both patients, the rash began to clear within 1 month of stopping semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseSymptom resolution after stopping semaglutide
    Study

    n = 2

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both patients began experiencing resolution of their symptoms within 1 month of discontinuing semaglutide.
    1 context sentence
    Summary · context
    Here, we present two cases of dermal hypersensitivity reactions in patients taking semaglutide for type II diabetes.
  2. 02HumanCase report or seriesSafety outcome

    In a 75-year-old woman with type II diabetes taking semaglutide for 10 months, an eruption with histology suggestive of drug hypersensitivity occurred.

    In plain wordsA 75-year-old woman taking semaglutide for 10 months developed a skin rash that looked like a drug allergy under the microscope.

    Peptide
    Semaglutide
    Outcome
    IncreaseDermal hypersensitivity reaction, case 1
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · 10 monthsAs given in this study (human).

    Source sentences

    Summary
    In the first case, a 75-year-old woman who had been taking semaglutide for 10 months presented with an eruption on her legs, back, and chest for 3 months duration.
    2 context sentences
    Summary · context
    Histology showed a subepidermal blister with eosinophils, suggestive of a drug hypersensitivity reaction.
    Summary · context
    Here, we present two cases of dermal hypersensitivity reactions in patients taking semaglutide for type II diabetes.
  3. 03HumanCase report or seriesSafety outcome

    In a 74-year-old man with type II diabetes taking semaglutide for 1 month, an eruption with histology suggestive of drug hypersensitivity occurred.

    In plain wordsA 74-year-old man taking semaglutide for 1 month developed a skin rash that looked like a drug allergy under the microscope.

    Peptide
    Semaglutide
    Outcome
    IncreaseDermal hypersensitivity reaction, case 2
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In the second case, a 74-year-old white man who had been taking semaglutide for 1 month presented with an eruption on the bilateral flanks and lower abdomen for 3 weeks duration.
    2 context sentences
    Summary · context
    Histology revealed perivascular inflammatory cell infiltrate with eosinophils, also suggestive of a drug hypersensitivity reaction.
    Summary · context
    Here, we present two cases of dermal hypersensitivity reactions in patients taking semaglutide for type II diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.